Abstract |
Choroidal neovascularization (CNV) is a major cause of vision loss in various ocular fundus diseases. The purpose of traditional therapies was to treat established CNV, but they only have limited effects. Drug treatment targeting the pathogenesis of CNV has become a hot research topic recently. Anecortave acetate is an angiostatic steroid which shows distinct mechanism of action in inhibiting neovascularization, making it different from the anti- VEGF agents ( Pegaptanib, Ranibizumab and Bevacizumab). As the studies on the mechanism of CNV going more deeply, effective treatment targeting the pathogenesis of CNV will bring hope for these patients.
|
Authors | Xia Li, Yu-sheng Wang |
Journal | [Zhonghua yan ke za zhi] Chinese journal of ophthalmology
(Zhonghua Yan Ke Za Zhi)
Vol. 44
Issue 6
Pg. 571-4
(Jun 2008)
ISSN: 0412-4081 [Print] China |
PMID | 19035252
(Publication Type: English Abstract, Journal Article, Review)
|
Chemical References |
- Angiogenesis Inhibitors
- Pregnadienediols
- anecortave acetate
|
Topics |
- Angiogenesis Inhibitors
(therapeutic use)
- Choroidal Neovascularization
(drug therapy)
- Humans
- Pregnadienediols
(therapeutic use)
|